Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits

Molecular Neurodegeneration

Volumn 8, Issue 1, 2013, Pages

  Carvalho, Miguel M ^a,b   Campos, Filipa L ^a,b   Coimbra, Bárbara ^a,b   Pêgo, José M ^a,b   Rodrigues, Carla ^a,b   Lima, Rui ^a,b   Rodrigues, Ana J ^a,b   Sousa, Nuno ^a,b   Salgado, António J ^a,b  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

Author keywords

6 OHDA; Bupropion; Emotion; Levodopa; Motor behavior; Parkinson's disease; Paroxetine

Indexed keywords

AMFEBUTAMONE; APOMORPHINE; LEVODOPA; OXIDOPAMINE; PAROXETINE;

ANHEDONIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR DISORDER; COGNITION; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOPAMINERGIC TRANSMISSION; FOREBRAIN; MOTOR DYSFUNCTION; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; RAT;

ADRENERGIC AGENTS; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BUPROPION; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; LEVODOPA; MOOD DISORDERS; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSONIAN DISORDERS; PAROXETINE; RATS; RATS, WISTAR;

ANIMALIA; RATTUS;

EID: 84876686906     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-8-14     Document Type: Article

References (79)

1. An essay on the shaking palsy. 1817. Parkinson J, J Neuropsychiatry Clin Neurosci 2002 14 223 236 discussion 222 10.1176/appi.neuropsych.14.2.223 11983801
2. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F, J Neurol Sci 1973 20 415 455 10.1016/0022-510X(73)90175-5 4272516
3. Parkinson's disease: mechanisms and models. Dauer W, Przedborski S, Neuron 2003 39 889 909 10.1016/S0896-6273(03)00568-3 12971891 (Pubitemid 37130207)
4. Ageing and Parkinson's disease: substantia nigra regional selectivity. Fearnley JM, Lees AJ, Brain 1991 114 Pt 5 2283 2301 1933245
5. Dopamine neuron systems in the brain: an update. Bjorklund A, Dunnett SB, Trends Neurosci 2007 30 194 202 10.1016/j.tins.2007.03.006 17408759 (Pubitemid 46654237)
6. The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Obeso JA, Marin C, Rodriguez-Oroz C, Blesa J, Benitez-Temino B, Mena-Segovia J, Rodriguez M, Olanow CW, Ann Neurol 2008 64 Suppl 2 30 46 19127584
7. Parkinson's disease: clinical features and diagnosis. Jankovic J, J Neurol Neurosurg Psychiatry 2008 79 368 376 10.1136/jnnp.2007.131045 18344392 (Pubitemid 351441488)
8. Non-motor symptoms of Parkinson's disease: diagnosis and management. Chaudhuri KR, Healy DG, Schapira AH, Lancet Neurol 2006 5 235 245 10.1016/S1474-4422(06)70373-8 16488379 (Pubitemid 43238347)
9. Pathology of Parkinsons-Disease-changes other than the nigrostriatal pathway. Jellinger KA, Mol Chem Neuropathol 1991 14 153 197 10.1007/BF03159935 1958262
10. Clinicopathological correlations in Parkinsons-Disease. Jellinger KA, Paulus W, Clin Neurol Neurosurg 1992 94 86 S88 1320531
11. Neurochemistry of Parkinson's disease: relation between striatal and limbic dopamine. Price KS, Farley IJ, Hornykiewicz O, Adv Biochem Psychopharmacol 1978 19 293 300 696462
12. Motivation, reward, and Parkinson's disease: influence of dopatherapy. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B, Neuropsychologia 2002 40 2257 2267 10.1016/S0028-3932(02)00108-2 12417456 (Pubitemid 35303365)
13. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Remy P, Doder M, Lees A, Turjanski N, Brooks D, Brain 2005 128 1314 1322 10.1093/brain/awh445 15716302 (Pubitemid 40826185)
14. Parkinson's disease and anxiety. Walsh K, Bennett G, Postgrad Med J 2001 77 89 93 10.1136/pmj.77.904.89 11161073 (Pubitemid 32120976)
15. The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A, Mov Disord 2009 24 1325 1332 10.1002/mds.22586 19412944
16. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB, J Am Geriatr Soc 2004 52 784 788 10.1111/j.1532-5415.2004.52219.x 15086662 (Pubitemid 38596500)
17. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Ungerstedt U, Eur J Pharmacol 1968 5 107 110 10.1016/0014-2999(68)90164-7 5718510
18. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Ungerstedt U, Arbuthnott GW, Brain Res 1970 24 485 493 10.1016/0006-8993(70)90187-3 5494536
19. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Deumens R, Blokland A, Prickaerts J, Exp Neurol 2002 175 303 317 10.1006/exnr.2002.7891 12061862 (Pubitemid 34634286)
20. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: Studies on medial forebrain bundle and striatal lesions. Chang JW, Wachtel SR, Young D, Kang UJ, Neuroscience 1999 88 617 628 10.1016/S0306-4522(98)00217-6 10197780 (Pubitemid 28480020)
21. Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model. Monville C, Torres EM, Dunnett SB, J Neurosci Methods 2006 158 219 223 10.1016/j.jneumeth.2006.06.001 16837051 (Pubitemid 44738080)
22. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. Yuan H, Sarre S, Ebinger G, Michotte Y, J Neurosci Methods 2005 144 35 45 10.1016/j.jneumeth.2004.10.004 15848237 (Pubitemid 40546300)
23. The "staircase test": a measure of independent forelimb reaching and grasping abilities in rats. Montoya CP, Campbell-Hope LJ, Pemberton KD, Dunnett SB, J Neurosci Methods 1991 36 219 228 10.1016/0165-0270(91)90048-5 2062117
24. The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP(+) toxicity: Role of BDNF gene expression. Hung HC, Lee EHY, Mol Brain Res 1996 41 16 26 10.1016/0169-328X(96)00062-9 (Pubitemid 26288140)
25. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson's disease. Rodriguez M, Barroso-Chinea P, Abdala P, Obeso J, Gonzalez-Hernandez T, Exp Neurol 2001 169 163 181 10.1006/exnr.2000.7624 11312569 (Pubitemid 32424333)
26. Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions. Truong L, Allbutt H, Kassiou M, Henderson JM, Behav Brain Res 2006 169 1 9 10.1016/j.bbr.2005.11.026 16413939 (Pubitemid 43277465)
27. A hitchhiker's guide to behavioral analysis in laboratory rodents. Sousa N, Almeida OF, Wotjak CT, Genes Brain Behav 2006 5 Suppl 2 5 24 16681797
28. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Levy R, Dubois B, Cereb Cortex 2006 16 916 928 16207933 (Pubitemid 43992442)
29. Mesolimbicocortical dopamine terminal fields are necessary for normal locomotor and investigatory exploration in rats. Fink JS, Smith GP, Brain Res 1980 199 359 384 10.1016/0006-8993(80)90695-2 7417789 (Pubitemid 10055940)
30. Differential-Effects of Mesocortical, Mesolimbic, and Mesostriatal Dopamine Depletion on Spontaneous, Conditioned, and Drug-Induced Locomotor-Activity. Jones GH, Robbins TW, Pharmacol Biochem Behav 1992 43 887 895 10.1016/0091-3057(92)90422-C 1448483
31. Involvement of basal ganglia transmitter systems in movement initiation. Hauber W, Prog Neurobiol 1998 56 507 540 10.1016/S0301-0082(98)00041-0 9775402 (Pubitemid 28407570)
32. Anxiety Disorders in Parkinson's Disease: Prevalence and Risk Factors. Dissanayaka NNW, Sellbach A, Matheson S, O'Sullivan JD, Silburn PA, Byrne GJ, Marsh R, Mellick GD, Mov Disord 2010 25 838 845 10.1002/mds.22833 20461800
33. L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease. Eskow Jaunarajs KLE, George JA, Bishop C, Neuroscience 2012 218 243 256 22659568
34. Nonmotor symptoms in Parkinson's disease: Investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. Branchi I, D'Andrea I, Armida M, Cassano T, Pèzzola A, Potenza RL, Morgese MG, Popoli P, Alleva E, J Neurosci Res 2008 86 2050 2061 10.1002/jnr.21642 18335518
35. Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat. Eskow Jaunarajs KLE, Dupre KB, Ostock CY, Button T, Deak T, Bishop C, Behav Pharmacol 2010 21 627 637 10.1097/FBP.0b013e32833e7e80 20838211
36. Topology of intrastriatal dopaminergic grafts determines functional and emotional outcome in neurotoxin-lesioned rats. Jungnickel J, Kalve L, Reimers L, Nobre A, Wesemann M, Ratzka A, Halfer N, Lindemann C, Schwabe K, Tollner K, Behav Brain Res 2011 216 129 135 10.1016/j.bbr.2010.07.023 20655334
37. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN, Neuroscience 2008 156 830 840 10.1016/j.neuroscience.2008.08.035 18817851
38. A systematic review of prevalence studies of depression in Parkinson's disease. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF, Mov Disord 2008 23 183 189 quiz 313 10.1002/mds.21803 17987654 (Pubitemid 351311545)
39. The mesolimbic dopamine reward circuit in depression. Nestler EJ, Carlezon WA Jr, Biol Psychiatry 2006 59 1151 1159 10.1016/j.biopsych.2005.09.018 16566899 (Pubitemid 44192421)
40. A systematic review of depression and mental illness preceding Parkinson's disease. Ishihara L, Brayne C, Acta Neurol Scand 2006 113 211 220 10.1111/j.1600-0404.2006.00579.x 16542159 (Pubitemid 43382593)
41. Effect of antidepressant drugs on 6-OHDA-treated mice in the FST. Chenu F, Dailly E, Bourin M, Eur Neuropsychopharmacol 2007 17 187 193 10.1016/j.euroneuro.2006.04.006 16757155 (Pubitemid 44779192)
42. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Santiago RM, Barbieiro J, Lima MMS, Dombrowski PA, Andreatini R, Vital MABF, Prog Neuropsychopharmacol Biol Psychiatry 2010 34 1104 1114 10.1016/j.pnpbp.2010.06.004 20547199
43. Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Winter C, von Rumohr A, Mundt A, Petrus D, Klein J, Lee T, Morgenstern R, Kupsch A, Juckel G, Behav Brain Res 2007 184 133 141 10.1016/j.bbr.2007.07.002 17698212 (Pubitemid 47498601)
44. Antidepressant-like properties of sarizotan in experimental Parkinsonism. Zhang XQ, Egeland M, Svenningsson P, Psychopharmacology 2011 218 621 634 10.1007/s00213-011-2356-7 21647579
45. Ventral tegmental lesions reduce overconsumption of normally preferred taste fluid in rats. Shimura T, Kamada Y, Yamamoto T, Behav Brain Res 2002 134 123 130 10.1016/S0166-4328(01)00461-2 12191798 (Pubitemid 34912691)
46. Partial lesion of the dopaminergic innervation of the ventral striatum induces "depressive-like" behavior of rats. Kuter K, Kolasiewicz W, Golembiowska K, Dziubina A, Schulze G, Berghauzen K, Wardas J, Ossowska K, Pharmacol Rep 2011 63 1383 1392 22358086
47. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM, J Neurosci 2003 23 6351 6356 12867520 (Pubitemid 36875637)
48. A dopaminergic basis for working memory, learning and attentional shifting in Parkinsonism. Moustafa AA, Sherman SJ, Frank MJ, Neuropsychologia 2008 46 3144 3156 10.1016/j.neuropsychologia.2008.07.011 18687347
49. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Owen AM, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, Lange KW, Robbins TW, Brain 1992 115 Pt 6 1727 1751 1486458 (Pubitemid 23054862)
50. Planning and spatial working memory: a positron emission tomography study in humans. Owen AM, Doyon J, Petrides M, Evans AC, Eur J Neurosci 1996 8 353 364 10.1111/j.1460-9568.1996.tb01219.x 8714706 (Pubitemid 26041333)
51. Spatial deficits in a mouse model of Parkinson disease. De Leonibus E, Pascucci T, Lopez S, Oliverio A, Amalric M, Mele A, Psychopharmacology 2007 194 517 525 10.1007/s00213-007-0862-4 17619858 (Pubitemid 47492993)
52. Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Da Cunha C, Gevaerd MS, Vital MABF, Miyoshi E, Andreatini R, Silveira R, Takahashi RN, Canteras NS, Behav Brain Res 2001 124 9 18 10.1016/S0166-4328(01)00211-X 11423161 (Pubitemid 32567554)
53. Dopamine depletion, stimulation or blockade in the rat disrupts spatial navigation and locomotion dependent upon beacon or distal cues. Whishaw IQ, Dunnett SB, Behav Brain Res 1985 18 11 29 10.1016/0166-4328(85)90165-2 3911980 (Pubitemid 16208491)
54. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Lindner MD, Cain CK, Plone MA, Frydel BR, Blaney TJ, Emerich DF, Hoane MR, Behav Brain Res 1999 102 1 16 10.1016/S0166-4328(98)00160-0 10403011 (Pubitemid 29314564)
55. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: Histological, neurochemical, motor and memory alterations. Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci MEM, Canteras NS, Da Cunha C, J Neurosci Methods 2005 148 78 87 10.1016/j.jneumeth. 2005.04.005 15939479 (Pubitemid 41423461)
56. Spatial learning in rats is impaired after degeneration of the nigrostriatal dopaminergic system. Mura A, Feldon J, Movement Dis 2003 18 860 871 10.1002/mds.10472 12889075 (Pubitemid 37021160)
57. Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy. Stacy MA, Murck H, Kroenke K, Prog Neuro-Psychopharmacol Biolog Psychiat 2010 34 57 61 10.1016/j.pnpbp.2009.09.023
58. Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy. Fetoni V, Soliveri P, Monza D, Testa D, Girotti F, J Neurol Neurosurg Psychiat 1999 66 541 544 10.1136/jnnp.66.4.541 10201434 (Pubitemid 29145696)
59. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Funkiewiez A, Ardouin C, Krack P, Fraix V, Van Blercom N, Xie J, Moro E, Benabid AL, Pollak P, Movement Dis 2003 18 524 530 10.1002/mds.10441 12722166 (Pubitemid 36656536)
60. Dose-response Relationship of Levodopa with Mood and Anxiety in Fluctuating Parkinsons-Disease-a Double-Blind, Placebo-Controlled Study. Maricle RA, Nutt JG, Valentine RJ, Carter JH, Neurology 1995 45 1757 1760 10.1212/WNL.45.9.1757 7675241
61. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM, Brain 2002 125 584 594 10.1093/brain/awf052 11872615 (Pubitemid 34194413)
62. Neurochemical and behavioral effects elicited by bupropion and diethylpropion in rats. Santamaria A, Arias HR, Behav Brain Res 2010 211 132 139 10.1016/j.bbr.2010.03.023 20307582
63. Bupropion hydrochloride produces conditioned hyperactivity in rats. Wilkinson JL, Bevins RA, Physiol Behav 2007 90 790 796 10.1016/j.physbeh.2007. 01.003 17300819 (Pubitemid 46483545)
64. Influence of sildenafil on the antidepressant activity of bupropion and venlafaxine in the forced swim test in mice. Socala K, Nieoczym D, Wyska E, Poleszak E, Wlaz P, Pharmacol Biochem Behav 2012 103 273 278 10.1016/j.pbb.2012.08.012 22940586
65. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. Cooper BR, Hester TJ, Maxwell RA, J Pharmacol Exp Ther 1980 215 127 134 6778989 (Pubitemid 11102264)
66. Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission. Bredeloux P, Dubuc I, Costentin J, Br J Pharmacol 2007 150 711 719 10.1038/sj.bjp.0707151 17293887 (Pubitemid 46440220)
67. Effects of bupropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats. Kitamura Y, Yagi T, Kitagawa K, Shinomiya K, Kawasaki H, Asanuma M, Gomita Y, N-S Arch Pharmacol 2010 382 151 158 10.1007/s00210-010-0521-x
68. Bupropion in the treatment of depression in Parkinson's disease. Zaluska M, Dyduch A, Int Psychogeriatrics/IPA 2011 23 325 327 10.1017/S1041610210001687
69. Successful treatment of depression in a Parkinson disease patient with bupropion. Leentjens AF, Verhey FR, Vreeling FW, Ned Tijdschr Geneeskd 2000 144 2157 2159 11086491
70. Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data. Scholtissen B, Verhey FR, Steinbusch HW, Leentjens AF, J Neural Transm 2006 113 59 73 10.1007/s00702-005-0368-3 16252066 (Pubitemid 41828957)
71. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Neurology 2012 78 1229 1236 10.1212/WNL.0b013e3182516244 22496199
72. A controlled trial of antidepressants in patients with Parkinson disease and depression. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A, Neurology 2009 72 886 892 10.1212/01.wnl.0000336340.89821.b3 19092112
73. Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports. Takahashi H, Kamata M, Yoshida K, Higuchi H, Shimizu T, Prog Neuro-Psychopharmacol Biolog Psychiat 2005 29 351 353 10.1016/j.pnpbp.2004.11.023 (Pubitemid 40202925)
74. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Francardo V, Recchia A, Popovic N, Andersson D, Nissbrandt H, Cenci MA, Neurobiol Disease 2011 42 327 340 10.1016/j.nbd.2011.01.024
75. Paxinos G, Watson C, The Rat Brain in Stereotaxic Coordinates San Diego, USA: Academic 4 1998
76. The impact of age on emotional and cognitive behaviours triggered by experimental neuropathy in rats. Leite-Almeida H, Almeida-Torres L, Mesquita AR, Pertovaara A, Sousa N, Cerqueira JJ, Almeida A, Pain 2009 144 57 65 10.1016/j.pain.2009.02.024 19398158
77. Mismatch between anxiety status and morphometric parameters in the amygdala and bed nucleus of the stria terminalis. Pego JM, Morgado P, Cerqueira JJ, Almeida OFX, Sousa N, Behav Brain Res 2006 173 320 325 10.1016/j.bbr.2006. 06.035 16904199 (Pubitemid 44291826)
78. A trans-dimensional approach to the behavioral aspects of depression. Bessa JM, Mesquita AR, Oliveira M, Pego JM, Cerqueira JJ, Palha JA, Almeida OF, Sousa N, Front Behav Neurosci 2009 3 1 19194528
79. The prefrontal cortex as a key target of the maladaptive response to stress. Cerqueira JJ, Mailliet F, Almeida OFX, Jay TM, Sousa N, J Neurosci 2007 27 2781 2787 10.1523/JNEUROSCI.4372-06.2007 17360899 (Pubitemid 46438976)